

# Comparative effectiveness of three TNF inhibitors for rheumatoid arthritis:

Quasi experiment with no large risk on confounding

Wietske Kievit, PhD

Radboud University Medical Center, Nijmegen, the Netherlands  
Department for Health Evidence, HTA section

---

Radboudumc

---

## Initiation of DREAM

- A registry of the use of TNF blocking agents in daily clinical practice was started on request of Dutch Health Care Institute (ZiNL)
- Objective: to determine the cost-effectiveness of these expensive 'new' drugs in daily clinical practice

---

Radboudumc

---

## Comparative effectiveness (1)

- Three different TNF alpha inhibitors on the market/ in the pipeline
- Which one to prefer?
- RCT was not granted

---

Radboudumc

---

## Comparative effectiveness (2)


- Difference in availability of TNFi
- → Quasi experiment
- Comparable to instrumental variable analysis

---

Radboudumc

## The DREAM study

- Inclusion of every RA patient that started with one of the TNF inhibitors since February 2003
- Collaboration between 11 hospitals in the Netherlands
- Regularly visits to assess medication use, effects and adverse events
- Clinical outcomes, patient reported outcomes; resource utilization



Radboudumc

## 707 with at least 1 year FU and fully accessible data (August 2007)

	Adalimumab N=267	Etanercept N=289	Infliximab N=151	p-value	Missing values (%)
% rheumatoid factor +	81,0	71,1	77,7	0.022	1 ←
% female	70,0	68,9	70,2	0.939	0
% with ≥ one erosion	71,7	65,3	72,7	0.157	1
Age	55,1 (12,6)	54,6 (14,2)	57,8 (13,4)	0.05	0 ←
Disease duration (years) <sup>§</sup>	7.7 (2.7-13.6)	6 (2.1-13.4)	7.7 (2.7-14.1)	0.356	1
N previous DMARDs <sup>§</sup>	3 (2-4)	3 (2-4.75)	3 (2-5)	0.385	0
HAQ	1,3 (0,7)	1,4 (0,7)	1,4(0,7)	0.176	10
DAS28	5,3 (1,3)	5,5 (1,2)	5,2 (1,3)	0.059	4 ←

Radboudumc

---

## Controlling for confounding


- Statistically significant differences, rheumatoid factor, age and DAS28 (outcome measures).
- Are the differences relevant?
  - Magnitude of the difference
  - association with the outcome
- Fitting propensity score failed because none of the factors predicted choice of treatment (is in line with results on previous slide)
- Linear mixed model for repeated measures, baseline DAS28 included by using random effect for patient and rheumatoid factor was included as a co-variant

---

Radboudumc

---


## Effectiveness: disease activity



---

Radboudumc

Kievit et al, Ann.Rheum.Dis., 2008; 67(9):1229-34



## Conclusion concerning comparison

- One TNFi was less effective compared to the other two TNFi
- Effect was relatively large (0.6 = clinically relevant)
- Results were plausible (dose finding studies show the same results)
- Consistent with results from other observational studies
- In this case very little differences in baseline prognostic factors due to:
  - Availability issues
  - No expected difference in performance of the drugs

---

## Conclusion

- In the absence of head-to-head comparisons, a comparison using observational data is first best alternative if
  - Outcome is accurately measured (objective vs subjective)
  - Loss of follow-up is minimized
  - Effect is large, consistent and biological plausible
  - Potential biases are corrected for sufficiently
  - Dose response relation